// App-Quantinova.ai

: Evaluation of the Effect of PBI-4050 Alone or in Combination with Pirfenidone or Nintedanib on Blood Biomarkers Linked to the Fibrotic Process in IPF Patients

Researchers

Presenter

  • L. Gagnon

Principal Investigators

  • B. Grouix

  • A. Laverdure

  • L. Foulkes

  • R. Sawtell

  • A. Hagerimana

  • P. Laurin

  • M. R. Kolb

  • J. Moran

  • J. Parker

Medical Centers

  • Prometic Biosciences Inc., Laval, QC, Canada.

  • McMaster University, Hamilton, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pirfenidone

  • Nintedanib

  • PBI4050

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II/III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved